Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9

Journal of Immunology

Volumn 185, Issue 4, 2010, Pages 2405-2415

  Simmons, Daimon P ^a   Canaday, David H ^b,c,d   Liu, Yi ^a   Li, Qing ^a,b   Huang, Alex ^a,c   Boom, W Henry ^b,c   Harding, Clifford V ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BETA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; HLA ANTIGEN CLASS 1; INTERFERON; LIPOPEPTIDE; OLIGODEOXYRIBONUCLEOTIDE; OVALBUMIN; PAM(3)CSK(4) PEPTIDE; TLR2 PROTEIN, MOUSE; TLR9 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; DENDRITIC CELL; IMMUNITY; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL LINE; CPG ISLAND; CROSS PRESENTATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT;

ANIMALS; BCG VACCINE; CELL LINE; CELLS, CULTURED; CPG ISLANDS; CROSS-PRIMING; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY ANTIGENS CLASS I; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; LIPOPEPTIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM TUBERCULOSIS; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 9;

EID: 77956894324     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0904005     Document Type: Article

References (61)

1. Mogues, T., M. E. Goodrich, L. Ryan, R. LaCourse, and R. J. North. 2001. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 193: 271-280.
2. Müller, I., S. P. Cobbold, H. Waldmann, and S. H. Kaufmann. 1987. Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect. Immun. 55: 2037-2041.
3. van Pinxteren, L. A. H., J. P. Cassidy, B. H. C. Smedegaard, E. M. Agger, and P. Andersen. 2000. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30: 3689-3698.
4. Flynn, J. L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19: 93-129.
5. Flynn, J. L., and J. D. Ernst. 2000. Immune responses in tuberculosis. Curr. Opin. Immunol. 12: 432-436.
6. Flynn, J. L., M. M. Goldstein, K. J. Triebold, B. Koller, and B. R. Bloom. 1992. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. USA 89: 12013-12017.
7. Kamath, A. B., J. Woodworth, X. Xiong, C. Taylor, Y. Weng, and S. M. Behar. 2004. Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection. J. Exp. Med. 200: 1479-1489.
8. Lewinsohn, D. A., E. Winata, G. M. Swarbrick, K. E. Tanner, M. S. Cook, M. D. Null, M. E. Cansler, A. Sette, J. Sidney, and D. M. Lewinsohn. 2007. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog. 3: 1240-1249.
9. Lewinsohn, D. M., M. R. Alderson, A. L. Briden, S. R. Riddell, S. G. Reed, and K. H. Grabstein. 1998. Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J. Exp. Med. 187: 1633-1640.
10. Urdahl, K. B., D. Liggitt, and M. J. Bevan. 2003. CD8+ T cells accumulate in the lungs of Mycobacterium tuberculosis-infected Kb-/-Db-/- mice, but provide minimal protection. J. Immunol. 170: 1987-1994.
11. Sousa, A. O., R. J. Mazzaccaro, R. G. Russell, F. K. Lee, O. C. Turner, S. Hong, L. Van Kaer, and B. R. Bloom. 2000. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc. Natl. Acad. Sci. USA 97: 4204-4208.
12. Irwin, S. M., A. A. Izzo, S. W. Dow, Y. A. Skeiky, S. G. Reed, M. R. Alderson, and I. M. Orme. 2005. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the M. tuberculosis72F polyprotein. Infect. Immun. 73: 5809-5816.
13. Billeskov, R., C. Vingsbo-Lundberg, P. Andersen, and J. Dietrich. 2007. Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. J. Immunol. 179: 3973-3981.
14. Lewinsohn, D. M., L. Zhu, V. J. Madison, D. C. Dillon, S. P. Fling, S. G. Reed, K. H. Grabstein, and M. R. Alderson. 2001. Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J. Immunol. 166: 439-446.
15. Kamath, A., J. S. Woodworth, and S. M. Behar. 2006. Antigen-specific CD8+ T cells and the development of central memory during Mycobacterium tuberculosis infection. J. Immunol. 177: 6361-6369.
16. Orme, I. M., and F. M. Collins. 1983. Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J. Exp. Med. 158: 74-83.
17. Hmama, Z., R. Gabathuler, W. A. Jefferies, G. de Jong, and N. E. Reiner. 1998. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. J. Immunol. 161: 4882-4893.
18. Noss, E. H., R. K. Pai, T. J. Sellati, J. D. Radolf, J. Belisle, D. T. Golenbock, W. H. Boom, and C. V. Harding. 2001. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J. Immunol. 167: 910-918.
19. Pancholi, P., A. Mirza, N. Bhardwaj, and R. M. Steinman. 1993. Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. Science 260: 984-986.
20. Wojciechowski, W., J. DeSanctis, E. Skamene, and D. Radzioch. 1999. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guérin involves class II transactivator and depends on the Nramp1 gene. J. Immunol. 163: 2688-2696.
21. Kincaid, E. Z., and J. D. Ernst. 2003. Mycobacterium tuberculosis exerts gene-selective inhibition of transcriptional responses to IFN-gamma without inhibiting STAT1 function. J. Immunol. 171: 2042-2049.
22. Pai, R. K., M. Convery, T. A. Hamilton, W. H. Boom, and C. V. Harding. 2003. Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J. Immunol. 171: 175-184.
23. Pai, R. K., M. E. Pennini, A. A. Tobian, D. H. Canaday, W. H. Boom, and C. V. Harding. 2004. Prolonged Toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages. Infect. Immun. 72: 6603-6614.
24. Tobian, A. A., N. S. Potter, L. Ramachandra, R. K. Pai, M. Convery, W. H. Boom, and C. V. Harding. 2003. Alternate class I MHC antigen processing is inhibited by Toll-like receptor signaling pathogen-associated molecular patterns: Mycobacterium tuberculosis 19-kDa lipoprotein, CpG DNA, and lipopolysaccharide. J. Immunol. 171: 1413-1422.
25. Remoli, M. E., E. Giacomini, G. Lutfalla, E. Dondi, G. Orefici, A. Battistini, G. Uzé, S. Pellegrini, and E. M. Coccia. 2002. Selective expression of type I IFN genes in human dendritic cells infected with Mycobacterium tuberculosis. J. Immunol. 169: 366-374.
26. Cho, H. J., T. Hayashi, S. K. Datta, K. Takabayashi, J. H. Van Uden, A. Horner, M. Corr, and E. Raz. 2002. IFN-alpha beta promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines. J. Immunol. 168: 4907-4913.
27. Tokunaga, T., H. Yamamoto, S. Shimada, H. Abe, T. Fukuda, Y. Fujisawa, Y. Furutani, O. Yano, T. Kataoka, T. Sudo, et al. 1984. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72: 955-962.
28. Pandey, A. K., Y. Yang, Z. Jiang, S. M. Fortune, F. Coulombe, M. A. Behr, K. A. Fitzgerald, C. M. Sassetti, and M. A. Kelliher. 2009. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog. 5: e1000500.
29. Durand, V., S. Y. Wong, D. F. Tough, and A. Le Bon. 2004. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol. Cell Biol. 82: 596-602.
30. Kamath, A. T., C. E. Sheasby, and D. F. Tough. 2005. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J. Immunol. 174: 767-776.
31. Datta, S. K., V. Redecke, K. R. Prilliman, K. Takabayashi, M. Corr, T. Tallant, J. DiDonato, R. Dziarski, S. Akira, S. P. Schoenberger, and E. Raz. 2003. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 170: 4102-4110.
32. Kuchtey, J., P. J. Chefalo, R. C. Gray, L. Ramachandra, and C. V. Harding. 2005. Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class IMHC mRNA. J. Immunol. 175: 2244-2251.
33. Thornley, T. B., N. E. Phillips, B. C. Beaudette-Zlatanova, T. G. Markees, K. Bahl, M. A. Brehm, L. D. Shultz, E. A. Kurt-Jones, J. P. Mordes, R. M. Welsh, et al. 2007. Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J. Immunol. 179: 6620-6629.
34. Pecora, N. D., A. J. Gehring, D. H. Canaday, W. H. Boom, and C. V. Harding. 2006. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. J. Immunol. 177: 422-429.
35. Drage, M. G., H.-C. Tsai, N. D. Pecora, T.-Y. Cheng, A. R. Arida, S. Shukla, R. E. Rojas, D. B. Moody, W. H. Boom, J. C. Sacchettini, and C. V. Harding. 2010. Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2. Nat. Struct. Mol. Biol. In press.
36. Thoma-Uszynski, S., S. Stenger, O. Takeuchi, M. T. Ochoa, M. Engele, P. A. Sieling, P. F. Barnes, M. Rollinghoff, P. L. Bolcskei, M. Wagner, et al. 2001. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291: 1544-1547.
37. Toshchakov, V., B. W. Jones, P. Y. Perera, K. Thomas, M. J. Cody, S. Zhang, B. R. Williams, J. Major, T. A. Hamilton, M. J. Fenton, and S. N. Vogel. 2002. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat. Immunol. 3: 392-398.
38. Kaisho, T., and S. Akira. 2003. Regulation of dendritic cell function through Toll-like receptors. Curr. Mol. Med. 3: 373-385.
39. Barbalat, R., L. Lau, R. M. Locksley, and G. M. Barton. 2009. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat. Immunol. 10: 1200-1207.
40. Bafica, A., C. A. Scanga, C. G. Feng, C. Leifer, A. Cheever, and A. Sher. 2005. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J. Exp. Med. 202: 1715-1724.
41. Giosué, S., M. Casarini, L. Alemanno, G. Galluccio, P. Mattia, G. Pedicelli, L. Rebek, A. Bisetti, and F. Ameglio. 1998. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 158: 1156-1162.
42. Palmero, D., K. Eiguchi, P. Rendo, L. Castro Zorrilla, E. Abbate, and L. J. González Montaner. 1999. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int. J. Tuberc. Lung Dis. 3: 214-218.
43. Ward, C. M., H. Jyonouchi, S. V. Kotenko, S. V. Smirnov, R. Patel, H. Aguila, G. McSherry, B. Dashefsky, and S. M. Holland. 2007. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency. Eur. J. Pediatr. 166: 981-985.
44. Telesca, C., M. Angelico, P. Piccolo, L. Nosotti, A. Morrone, C. Longhi, M. Carbone, and L. Baiocchi. 2007. Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J. Infect. 54: e223-e226.
45. Manca, C., L. Tsenova, A. Bergtold, S. Freeman, M. Tovey, J. M. Musser, C. E. Barry, III, V. H. Freedman, and G. Kaplan. 2001. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc. Natl. Acad. Sci. USA 98: 5752-5757.
46. Kuchtey, J., S. A. Fulton, S. M. Reba, C. V. Harding, and W. H. Boom. 2006. Interferon-alphabeta mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guérin infection. Immunology 118: 39-49.
47. Bouchonnet, F., N. Boechat, M. Bonay, and A. J. Hance. 2002. Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect. Immun. 70: 3020-3025.
48. Giacomini, E., M. E. Remoli, V. Gafa, M. Pardini, L. Fattorini, and E. M. Coccia. 2009. IFN-beta improves BCG immunogenicity by acting on DC maturation. J. Leukoc. Biol. 85: 462-468.
49. Sikora, A. G., N. Jaffarzad, Y. Hailemichael, A. Gelbard, S. W. Stonier, K. S. Schluns, L. Frasca, Y. Lou, C. Liu, H. A. Andersson, et al. 2009. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J. Immunol. 182: 7398-7407.
50. Prabhakar, S., Y. Qiao, Y. Hoshino, M. Weiden, A. Canova, E. Giacomini, E. Coccia, and R. Pine. 2003. Inhibition of response to alpha interferon by Mycobacterium tuberculosis. Infect. Immun. 71: 2487-2497.
51. Prabhakar, S., Y. Qiao, A. Canova, D. B. Tse, and R. Pine. 2005. IFN-alpha beta secreted during infection is necessary but not sufficient for negative feedback regulation of IFN-alpha beta signaling by Mycobacterium tuberculosis. J. Immunol. 174: 1003-1012.
52. Mariotti, S., R. Teloni, E. Iona, L. Fattorini, G. Romagnoli, M. C. Gagliardi, G. Orefici, and R. Nisini. 2004. Mycobacterium tuberculosis diverts alpha interferon-induced monocyte differentiation from dendritic cells into immunoprivileged macrophage-like host cells. Infect. Immun. 72: 4385-4392.
53. Lichtner, M., R. Rossi, F. Mengoni, S. Vignoli, B. Colacchia, A. P. Massetti, I. Kamga, A. Hosmalin, V. Vullo, and C. M. Mastroianni. 2006. Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response. Clin. Exp. Immunol. 143: 329-337.
54. Dudani, R., Y. Chapdelaine, H. Faassen Hv, D. K. Smith, H. Shen, L. Krishnan, and S. Sad. 2002. Multiple mechanisms compensate to enhance tumor-protective CD8(+) T cell response in the long-term despite poor CD8(+) T cell priming initially: comparison between an acute versus a chronic intracellular bacterium expressing a model antigen. J. Immunol. 168: 5737-5745.
55. Gray, R. C., J. Kuchtey, and C. V. Harding. 2007. CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs. J. Leukoc. Biol. 81: 1075-1085.
56. Kadowaki, N., S. Ho, S. Antonenko, R. W. Malefyt, R. A. Kastelein, F. Bazan, and Y. J. Liu. 2001. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194: 863-869.
57. Hoene, V., M. Peiser, and R. Wanner. 2006. Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19. J. Leukoc. Biol. 80: 1328-1336.
58. Semnani, R. T., P. G. Venugopal, C. A. Leifer, S. Mostböck, H. Sabzevari, and T. B. Nutman. 2008. Inhibition of TLR3 and TLR4 function and expression in human dendritic cells by helminth parasites. Blood 112: 1290-1298.
59. Edwards, A. D., S. S. Diebold, E. M. Slack, H. Tomizawa, H. Hemmi, T. Kaisho, S. Akira, and C. Reis e Sousa. 2003. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33: 827-833.
60. Drennan, M. B., D. Nicolle, V. J. Quesniaux, M. Jacobs, N. Allie, J. Mpagi, C. Frémond, H. Wagner, C. Kirschning, and B. Ryffel. 2004. Toll-like receptor 2-deficient mice succumb to Mycobacterium tuberculosis infection. Am. J. Pathol. 164: 49-57.
61. Dolganiuc, A., S. Chang, K. Kodys, P. Mandrekar, G. Bakis, M. Cormier, and G. Szabo. 2006. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 177: 6758-6768.